Centre Caps Cancer Drug Trade Margins at 30%, Patients Expected to Save ₹2,500 Crore Annually

The Government of India has approved a major intervention to reduce the cost of cancer treatment by limiting trade margins on non-scheduled anti-cancer medicines to 30% of their Maximum Retail Price (MRP). The decision, announced by the Department of Pharmaceuticals on October 8, 2026, aims to address excessive mark-ups in the pharmaceutical supply chain and make essential cancer treatments more affordable. The Government estimates that the measure could reduce prices of affected medicines by up to 70% and generate annual savings of approximately ₹2,500 crore for patients and their families.

The development gained further attention on October 12, 2026, when the Central Government informed the Supreme Court about its decision to regulate trade margins on anti-cancer medicines. The Government also outlined the process for identifying the medicines that would come under the new arrangement. The announcement represents an expansion of India’s existing pharmaceutical price-control framework, which already regulates essential medicines included in the National List of Essential Medicines.

The new decision specifically addresses non-scheduled anti-cancer medicines, which are not subject to the same government-fixed ceiling prices applicable to scheduled formulations. According to the National Pharmaceutical Pricing Authority (NPPA), some medicines in this category have carried exceptionally high mark-ups between the supply price and the price ultimately charged to patients. By restricting trade margins, the Government intends to reduce this difference while maintaining the availability of important cancer medicines.

An expert committee under the Directorate General of Health Services will finalise the list of medicines covered by the intervention. The NPPA will subsequently take the necessary decision and issue the official notification. The policy has received government approval, but its application to individual medicines remains subject to the notification process.

Government Approves 30% Trade Margin Ceiling on Non-Scheduled Cancer Medicines

The Department of Pharmaceuticals, under the Ministry of Chemicals and Fertilizers, announced the expanded price-control measure on October 8, 2026. The decision targets the margins charged as anti-cancer medicines move through the pharmaceutical distribution chain before reaching patients.

Trade margins represent the difference between the price at which a medicine enters a particular stage of distribution and the price charged further along the supply chain. Depending on the arrangements between manufacturers, distributors, stockists and retailers, these margins can contribute substantially to the final price paid by patients.

The Government’s decision limits the permitted trade margin on covered non-scheduled cancer medicines to 30% of the MRP. This is not a uniform 30% reduction in medicine prices, nor does it mean that every cancer medicine will carry the same final selling price. The actual reduction will depend on the existing price structure of each formulation and the regulatory methodology applied by NPPA.

The intervention seeks to address excessive distribution-related mark-ups without replacing the established price-control mechanism for essential medicines. Scheduled cancer drugs will continue to be governed by their applicable ceiling prices, while the new arrangement extends more direct price protection to additional non-scheduled medicines.

Supreme Court Raises Concerns Over High Medicine Prices

The issue of excessive medicine pricing has also been examined by the Supreme Court of India. During proceedings on October 12, the Central Government informed a Bench comprising Justices Vikram Nath and Sandeep Mehta that it had approved the 30% trade margin ceiling for anti-cancer medicines.

Solicitor General Tushar Mehta, representing the Union Government, explained that the authorities would notify the list of medicines covered by the measure. The list could subsequently be updated to reflect developments in the pharmaceutical market and public health requirements.

The Supreme Court’s concerns extend beyond cancer treatment. During the proceedings, the Bench questioned substantial differences between the prices at which medical products are supplied to retailers and the maximum retail prices charged to consumers. The Court also examined whether the Government should consider broader measures addressing excessive margins on other medicines and medical devices.

The matter was listed for further hearing on October 27, 2026. The Court’s observations brought additional attention to the wider question of pharmaceutical affordability, although the Government’s confirmed October 8 policy decision specifically concerns non-scheduled anti-cancer medicines.

NPPA Finds Cancer Drug Mark-Ups Averaging 170%

The Government’s intervention follows an analysis of pharmaceutical market data by the National Pharmaceutical Pricing Authority. According to the Department of Pharmaceuticals, non-scheduled anti-cancer medicines carried an average price mark-up of approximately 170%, with mark-ups reaching 700% or more in some cases.

Such differences can arise as medicines move through various stages of distribution. The price charged to a patient may therefore be substantially higher than the price at which the medicine entered the supply chain.

The Government also identified significant differences in medicine prices across different retail channels. Patients purchasing medicines from retail pharmacies, hospital pharmacies and online pharmacies may encounter varying prices for pharmaceutical products, depending on their distribution arrangements and commercial practices.

These differences become particularly important when patients require expensive medicines over extended treatment periods. A substantial mark-up on an already costly medicine can increase household expenditure and place additional financial pressure on families.

The NPPA findings provided the Government with evidence for examining whether the existing regulatory arrangements adequately protected patients purchasing non-scheduled cancer medicines. The new trade margin ceiling seeks to address this specific pricing problem.

Cancer Treatment Costs Place Heavy Financial Pressure on Families

Cancer treatment can involve several stages of medical care, including diagnosis, surgery, radiotherapy, systemic drug treatment and follow-up monitoring. The medicines prescribed depend on the type and stage of cancer, the patient’s medical condition and the treatment plan recommended by qualified specialists.

Some patients require medicines over extended periods, while others receive several treatment cycles involving costly pharmaceutical products. These expenses may be accompanied by charges for hospital services, diagnostic investigations, travel and accommodation.

The Department of Pharmaceuticals has acknowledged that cancer treatment imposes a substantial financial burden on patients and their families, particularly when significant expenses must be paid directly by households.

The Government’s October 8 announcement identified rising cancer incidence and high treatment costs as important reasons for strengthening pharmaceutical price protection. It also emphasised that excessive medicine margins can increase expenses without necessarily reflecting corresponding increases in manufacturing or therapeutic value.

Reducing avoidable mark-ups can therefore improve affordability for patients who depend on medicines covered by the new intervention. The extent of actual savings will depend on the final notified list, the existing prices of individual products and compliance with the revised regulatory requirements.

How the 30% Trade Margin Cap Will Work

The new arrangement focuses on the difference between prices within the pharmaceutical distribution chain and the maximum price charged to patients. Its purpose is to limit excessive trade margins rather than establish a single uniform price for all medicines used in cancer treatment.

Under the Government’s decision, the permitted trade margin for covered non-scheduled anti-cancer medicines will not exceed 30% of the MRP. The NPPA will determine the applicable regulatory requirements after the expert committee finalises the list of medicines.

The difference between limiting trade margins and directly fixing a medicine’s ceiling price is important. A ceiling price establishes the maximum permitted price for a specified formulation under the applicable regulatory framework. Trade margin rationalisation instead regulates the margin permitted within the medicine’s supply and sale arrangements.

For example, a pharmaceutical product may pass through several commercial stages before reaching a patient. If the combined margins within the regulated portion of that chain are excessive, the final selling price can become substantially higher than the relevant supply price. Limiting the permitted margin can reduce the amount added during distribution.

The exact revised MRP for each medicine will depend on the regulatory calculation and the final NPPA notification. Patients should therefore refer to notified prices rather than assume that every covered medicine will automatically become 70% cheaper.

Government Expects Cancer Medicine Prices to Fall by Up to 70%

The Department of Pharmaceuticals estimates that its expanded trade margin intervention could reduce the prices of affected cancer medicines by as much as 70%. This estimate reflects the potential for substantial reductions where existing distribution margins are particularly high.

The Government also projects annual patient savings of approximately ₹2,500 crore. These savings would arise from reductions in the prices charged for medicines covered by the new arrangement, subject to the final scope and implementation of the policy.

The projected benefits are particularly relevant because cancer patients may require repeated purchases of expensive medicines. Even a moderate reduction in the price of a frequently prescribed medicine can lower cumulative treatment expenditure over several months.

However, the projected ₹2,500 crore represents an estimate of future savings, not a financial benefit already realised. The final outcome will depend on which medicines are notified, their existing market prices, sales volumes and the extent to which manufacturers and distributors implement the revised requirements.

The Government’s assessment nevertheless indicates that excessive margins represent a significant component of the affordability problem for certain non-scheduled cancer medicines.

Earlier 2019 Price Intervention Saved Patients ₹984 Crore Annually

The October 2026 decision builds upon an earlier intervention introduced by the National Pharmaceutical Pricing Authority in February 2019.

Acting under Paragraph 19 of the Drugs (Prices Control) Order, 2013, NPPA imposed a trade margin ceiling on 42 selected non-scheduled anti-cancer medicines. The measure sought to reduce excessive margins while improving access to medicines that were not otherwise covered by scheduled price ceilings.

According to the Department of Pharmaceuticals, the 2019 intervention resulted in reductions of up to 91% in the MRPs of affected medicines. The Government reported annual patient savings of approximately ₹984 crore across 526 medicine brands.

Official NPPA information has also recorded substantial average price reductions across the affected brands, demonstrating the practical effects of limiting unusually high margins.

The experience provided an important precedent for the expanded intervention approved in October 2026. It showed that regulating margins within the distribution chain could produce significant reductions in patient expenditure without requiring every medicine to be brought under the same scheduled price-control mechanism.

The Government has drawn upon this earlier experience while developing its latest measures for a wider range of non-scheduled anti-cancer medicines.

Essential Cancer Medicines Already Covered by Government Price Ceilings

India regulates pharmaceutical prices primarily through the Drugs (Prices Control) Order, 2013, which is administered by the Department of Pharmaceuticals through the National Pharmaceutical Pricing Authority.

Medicines included in Schedule I of the Order are subject to government-fixed ceiling prices. The scheduled list is linked to the National List of Essential Medicines issued by the Ministry of Health and Family Welfare.

In an official parliamentary reply issued on February 3, 2026, the Government confirmed that NPPA had fixed ceiling prices for 131 scheduled anti-cancer formulations. These formulations fall under the category covering anti-cancer agents, immunosuppressive medicines and medicines used in palliative care.

Manufacturers of scheduled medicines, whether branded or generic, must comply with the notified ceiling prices and applicable tax provisions. The regulatory framework also contains mechanisms for fixing retail prices of certain new drugs.

Non-scheduled medicines are subject to different provisions, including restrictions on annual increases in their MRPs. However, these provisions do not operate in the same manner as direct ceiling prices for scheduled formulations.

The October 2026 decision adds another layer of regulation by targeting excessive trade margins on non-scheduled anti-cancer medicines. This expands price protection while retaining the existing structure of pharmaceutical price regulation.

Expert Committee to Finalise List of Cancer Medicines

The Government has assigned responsibility for finalising the list of medicines covered by the new intervention to an expert committee under the Directorate General of Health Services.

The committee will examine the relevant medicines before the National Pharmaceutical Pricing Authority takes the necessary regulatory decision and issues the notification.

The Department of Pharmaceuticals has confirmed that the intervention will extend across different categories of non-scheduled anti-cancer medicines. Its stated scope includes branded and generic products, domestically manufactured and imported formulations, and patented as well as non-patented medicines.

This approach is significant because expensive cancer treatment can involve products manufactured under different commercial and intellectual property arrangements. Limiting the intervention exclusively to one category could leave other medicines outside its intended protection.

The Government has also indicated that the notified list may be reviewed as market conditions and public health requirements change. Such reviews would allow the authorities to consider additional medicines where appropriate.

As of October 12, 2026, the final list and corresponding NPPA notification remained the essential next steps before the expanded measure could be applied to identified products.

Manufacturers Required to Maintain Production Levels

An important aspect of pharmaceutical price regulation is ensuring that affordability measures do not disrupt the availability of medicines.

The Department of Pharmaceuticals has stated that manufacturers of non-scheduled anti-cancer medicines will be required to maintain their existing production levels under the new intervention.

This provision is intended to protect patients against potential shortages while the Government introduces stricter limits on trade margins. Maintaining supply is particularly important for cancer treatment because interruptions in access to prescribed medicines can affect treatment schedules.

The requirement also recognises that medicine affordability involves both price and availability. A medicine with a lower regulated price provides limited practical benefit if patients cannot obtain it when required.

By including production continuity within the intervention, the Government aims to balance price reductions with the continued availability of affected pharmaceutical products.

The effectiveness of this approach will depend on the implementation requirements included in the final notification and the monitoring undertaken by the relevant authorities.

Supreme Court Seeks Wider Review of Medicine and Medical Device Pricing

While the Government’s immediate intervention concerns cancer medicines, the Supreme Court has raised questions about pricing practices across the wider pharmaceutical and medical device sectors.

During the October 12 proceedings, the Bench examined the substantial differences that can arise between supply prices and the MRPs of certain medical products. The discussion included cardiac stents, highlighting the Court’s concern that excessive mark-ups may not be confined to oncology medicines.

The Government informed the Court that coronary stents were already subject to price regulation. NPPA’s official records confirm that coronary stents and certain other medical devices have previously been brought under price-control measures.

The Court nevertheless sought further examination of the broader pricing problem, particularly where significant differences between supply prices and consumer prices could impose unreasonable financial burdens on patients.

The next hearing was scheduled for October 27, 2026. Any broader regulatory intervention would require further government action and should be distinguished from the cancer medicine margin ceiling already approved.

The proceedings have brought attention to the importance of transparency and effective regulation throughout the pharmaceutical and medical device supply chain.

NPPA Plays Central Role in Protecting Patients from Excessive Drug Prices

The National Pharmaceutical Pricing Authority serves as India’s principal pharmaceutical pricing regulator under the Department of Pharmaceuticals.

Its responsibilities include fixing ceiling prices for scheduled medicines, determining applicable retail prices for certain new formulations and monitoring compliance with the Drugs (Prices Control) Order, 2013.

The authority also monitors price increases in non-scheduled medicines and can implement regulatory interventions in accordance with the provisions of the Order.

In July 2026, the Department of Pharmaceuticals informed Parliament that NPPA had fixed ceiling prices for 935 scheduled formulations across therapeutic categories. These medicines are linked to the National List of Essential Medicines, which provides a foundation for India’s essential drug price-control framework.

The expansion of cancer medicine trade margin regulation adds to NPPA’s responsibilities in protecting consumers against excessive pharmaceutical pricing.

Effective enforcement will require clear notifications, accurate price information and compliance by manufacturers and the relevant distribution channels.

The authority’s previous experience with anti-cancer medicine margin rationalisation provides an established regulatory basis for implementing the expanded measure.

Government Strengthens Affordability Through Pharmaceutical Policy Measures

The new trade margin ceiling forms part of India’s wider efforts to improve access to medicines and reduce treatment expenditure.

Pharmaceutical affordability depends on several factors, including medicine prices, taxation, manufacturing costs, distribution arrangements and the availability of alternative products. Government policy therefore uses different mechanisms to address these components.

Scheduled medicines are regulated through notified ceiling prices, while selected non-scheduled products may be covered by specific trade margin interventions. Tax measures and initiatives supporting domestic pharmaceutical manufacturing also influence the broader affordability environment.

The Union Budget 2026–27 proposed additional customs duty relief for identified life-saving medicines, including drugs relevant to cancer treatment. Such measures are separate from trade margin regulation but share the broader objective of reducing costs associated with healthcare.

India’s pharmaceutical manufacturing capabilities also play an important role in medicine availability. Domestic production of generic medicines and other pharmaceutical products supports access within India while contributing to international supply.

The October 2026 decision concentrates specifically on excessive margins within the distribution chain, complementing the other regulatory and industrial measures already in place.

Cancer Patients Expected to Benefit from Greater Price Transparency

The expanded trade margin regulation has the potential to improve transparency in the pricing of certain anti-cancer medicines.

When prices vary substantially between different sales channels, patients may find it difficult to understand whether they are paying a reasonable amount for prescribed treatment. This uncertainty becomes more serious when the medicine is expensive and alternatives are limited.

Regulated margins can provide a clearer framework for determining permissible prices and reducing unusually large differences between supply costs and retail charges.

The actual benefit to individual patients will depend on whether their prescribed medicines appear on the final notified list and the revised prices applicable to those products.

Patients should continue following their treating oncologist’s medical advice. Decisions concerning cancer medicines depend on clinical considerations, and price changes should not lead patients to substitute or discontinue prescribed treatments without professional guidance.

The Government’s intervention focuses on improving financial accessibility while preserving the availability of medicines required for cancer care.

India Moves Towards More Affordable Cancer Treatment

The Government’s decision to limit trade margins on non-scheduled anti-cancer medicines to 30% of the MRP represents an important development in India’s pharmaceutical affordability policy.

The intervention addresses significant pricing disparities identified by NPPA, including average mark-ups of approximately 170% and substantially higher margins in certain cases. By regulating these margins, the Government expects to reduce the prices of affected medicines by up to 70% and generate annual savings of approximately ₹2,500 crore.

The measure builds upon the 2019 initiative covering 42 anti-cancer medicines, which produced reported annual savings of ₹984 crore across 526 brands. It also complements the existing price ceilings applicable to essential cancer medicines under the Drugs (Prices Control) Order, 2013.

The Supreme Court’s examination of medicine pricing has brought wider attention to the need for effective regulation and transparency across pharmaceutical distribution. Meanwhile, the Government’s commitment to maintaining production levels seeks to ensure that price reductions do not compromise the availability of important treatments.

With the proposed expansion of trade margin controls, continued regulatory oversight and greater attention to medicine affordability, India is strengthening its efforts to reduce the financial burden of cancer treatment and improve access to essential healthcare.

The final notification by NPPA will mark the next important stage in translating the approved policy into revised medicine prices and measurable savings for patients.

---

References

1. Press Information Bureau, Government of India
Ministry of Chemicals and Fertilizers — Department of Pharmaceuticals
Government Expands Cancer Medicine Price Controls; Cancer Patients Expected to Save ₹2,500 Crore Annually
Published: October 8, 2026, 10:04 PM
Release ID: 2321092
www.pib.gov.in/PressReleasePage.aspx?PRID=2321092

2. Akashvani News — News on AIR
Centre Decides to Cap Cancer Drug Margins at 30%
Published: October 12, 2026, 8:51 PM
newsonair.gov.in/centre-decides-to-cap-cancer-drug-margins-at-30/

3. Press Information Bureau, Government of India
Ministry of Chemicals and Fertilizers — Department of Pharmaceuticals
Non-Inclusion of Cancer Medication Under Price Control
Published: February 3, 2026
Release ID: 2222520
www.pib.gov.in/PressReleasePage.aspx?PRID=2222520

4. Press Information Bureau, Government of India
Ministry of Chemicals and Fertilizers — Department of Pharmaceuticals
Cost of Essential Cancer Drugs
Published: March 13, 2026
Release ID: 2239575
www.pib.gov.in/PressReleasePage.aspx?PRID=2239575

5. Press Information Bureau, Government of India
Ministry of Chemicals and Fertilizers — Department of Pharmaceuticals
Price Regulation of Essential Medicines
Published: July 28, 2026
Release ID: 2290387
www.pib.gov.in/PressReleasePage.aspx?PRID=2290387

6. National Pharmaceutical Pricing Authority, Government of India
Trade Margin Rationalisation of Non-Scheduled Anti-Cancer Medicines — 2019
Official pharmaceutical price-control orders and notifications.
nppaindia.nic.in

7. Department of Pharmaceuticals, Government of India
Drugs (Prices Control) Order, 2013
Official framework for pharmaceutical price regulation in India.
pharma-dept.gov.in

---